SITE MAP | TERMS OF USE | © 2010 RHYTHM PHARMACEUTICALS
RM-131: Ghrelin Peptide Agonist
A new drug class for the treatment of GI functional disorders
Ghrelin is a peptide hormone produced by the gut that plays a central role in feeding regulation, nutrient absorption, GI motility, and energy homeostasis. Ghrelin also possesses anti-inflammatory properties, suppressing a range of inflammatory cytokines. Given the potent prokinetic effects of ghrelin, GI motility disorders are targeted clinical applications for ghrelin, particularly gastroparesis, postoperative ileus, and opioid-induced constipation.
RM-131 was derived from the natural ghrelin sequence and optimized for the properties of stimulating GI motility, weight gain, and anti-inflammatory activity—with enhanced stability and pharmacokinetics. The compound is uniquely suited for GI motility disorders as it reverses both surgical and opiate-induced ileus in animal models due to a direct prokinetic effect. RM-131 reverses body weight loss in cachexia models.
Development Stage:
RM-131 is in Phase I clinical development for the treatment of diabetic gastroparesis (DG).
A new drug class for the treatment of GI functional disorders
Ghrelin is a peptide hormone produced by the gut that plays a central role in feeding regulation, nutrient absorption, GI motility, and energy homeostasis. Ghrelin also possesses anti-inflammatory properties, suppressing a range of inflammatory cytokines. Given the potent prokinetic effects of ghrelin, GI motility disorders are targeted clinical applications for ghrelin, particularly gastroparesis, postoperative ileus, and opioid-induced constipation.
RM-131 was derived from the natural ghrelin sequence and optimized for the properties of stimulating GI motility, weight gain, and anti-inflammatory activity—with enhanced stability and pharmacokinetics. The compound is uniquely suited for GI motility disorders as it reverses both surgical and opiate-induced ileus in animal models due to a direct prokinetic effect. RM-131 reverses body weight loss in cachexia models.
Development Stage:
RM-131 is in Phase I clinical development for the treatment of diabetic gastroparesis (DG).
